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Background/aim: We aimed to investigate the effect of long-term use of dexamethasone and prednisolone on the reversal effect of
sugammadex.
Materials and methods: TTwenty-four male Wistar albino rats were divided into three groups. Dexamethasone (600 µg/kg) was given to
group D, prednisolone (10 mg/kg) was given to group P, and an equivalent volume of saline per day was administered intraperitoneally to
group S for 14 days, respectively. The left hemidiaphragm with attached phrenic nerve was maintained in Krebs solution. Sugammadex
(30 µmol/L) was applied while rocuronium (10 µmol/L) was present in an organ bath and a single twitch was obtained. The right
hemidiaphragm was used for both adult (ɛ-subunit) and fetal nicotinic acetylcholine receptor (AChR) (ɣ-subunit) determination using
polymerase chain reaction.
Results: All animals lost weight, except group S. The mean baseline single-twitch tension was lower in both group D (14.4 ± 1.7 g) and
group P (12.68 ± 0.05 g) than group S (16.8 ± 0.5 g) (P < 0.001). When sugammadex was added to the organ bath while rocuronium was
present, the single twitch was measured to be lower in both group D (11.7 ± 0.7 g) and group P (11.5 ± 0.78 g) than group S (16.5 ± 0.24
g) (P < 0.001). ɣ-AChR expression was higher in both dexamethasone and prednisolone than in saline.
Conclusion: Long-term medication with dexamethasone and prednisolone caused muscle weakness, resistance to neuromuscular
blockers, and upregulation of immature γ-AChR and reduced the neuromuscular reversal effect of sugammadex.
Key words: Sugammadex, dexamethasone, prednisolone, acetylcholine receptors, neuromuscular blockers

1. Introduction
Glucocorticoid drugs are widely used for the longterm treatment of disease and symptoms such as sepsis,
edema, anaphylaxis, and inflammatory disease. Chronic
glucocorticoid treatment can cause muscle atrophy and
this muscle weakness after glucocorticoid treatment
can be associated with increased synthesis and release
of acetylcholine; therefore, resistance to the effect of
neuromuscular blocking drug occurs (1–6).
The effect of long-term prednisolone medication on
atracurium- and rocuronium-induced neuromuscular
blockage has already been indicated by Soeltsz et al.
The authors showed that patients who received longterm prednisolone medication had shorter duration of
atracurium- and rocuronium-induced neuromuscular
blockage (7,8).
Nicotinic acetylcholine receptors (nAChRs) have four
different subunits in a pentameric structure. Muscle-type

nAChRs include two subtypes: the adult or junctional
mature form (ε-AChR) comprises an α2βδε subunit, and
the fetal immature form (γ-AChR) contains an α2βδγ
subunit. The immature fetal form is usually expressed
in fetal life. Fetal-type nAChRs have shorter open
times than adult-type nAChRs (9). When the muscles
are innervated, γ-AChR is replaced by ε-AChR. Some
pathologic conditions such as immobilizations, burns,
and denervation induce upregulation of expression to
immature subtypes (10–13). Furthermore, glucocorticoid
treatment upregulates the synthesis and expression of
junctional nAChRs (6,14–16).
Sugammadex is a ɣ-cyclodextrin that reverses the
neuromuscular block induced by rocuronium and
vecuronium. It has a rapid onset and high efficacy in the
reversal of deep neuromuscular blockage (17).
In the present study, we aimed to investigate the effect
of long-term usage of prednisolone and dexamethasone on
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sugammadex reversal. We hypothesized that sugammadex
was less effective with chronic glucocorticoid use and this
could be due to both muscle weakness and an increase
in immature acetylcholine receptors. Our primary
objective was to investigate the effect of long-term use
of prednisolone and dexamethasone on sugammadex
reversal. The secondary outcome was the detection of
immature acetylcholine receptors in glucocorticoid-treated
rat diaphragms.
2. Materials and methods
All experiments reported in this paper were performed
at the Department of Biophysics and Medical Biology of
Çukurova University, Turkey, in collaboration with the
Department of Anesthesiology and Intensive Care, Faculty
of Medicine, Çukurova University, Turkey. The study was
approved by the Çukurova University Ethics Committee
of Animal Research (Permission Date: 26 February 2016,
Ethics Number: 2/3)
2.1. Animals and muscle preparation
Twenty-four male Wistar albino rats (280–320 g) were
used for this study. They were maintained for 1 week in
the biophysics laboratory for adaptation. They were fed
standard rat chow and tap water ad libitum during the
experimental period. The temperature and humidity were
monitored continuously throughout the experimental
period. The animals were kept in an environmentally
controlled room at 21–23 °C and relative humidity of
40%–60%, with a light/dark cycle of 12/12 h. In this study,
14-day glucocorticoid treatment was considered a longterm treatment, as previously reported in the literature
(15,18,19). Rats were divided into 3 groups receiving
dexamethasone (group D; n = 8), prednisolone (group
P; n = 8), or saline (group S; n = 8). In group D, 600 µg/
kg dexamethasone (Dekort ampule, 8 mg/2 mL, Deva
Holding AŞ, Turkey) was applied intraperitoneally daily for
14 days (dosage was taken from previous studies) (16,20).
In group P, 10 mg/kg prednisolone (Prednol-L ampule, 20
mg/mL, Mustafa Nevzat AŞ, Turkey) was administered
intraperitoneally for 14 days (dosage as used by Shin et al.)
(3). The drug dosages were chosen taking into consideration
the equivalents of the lowest doses that could cause muscle
atrophy. The saline group (group S) received an equivalent
volume of saline per day (0.9% NaCl). All drugs were given
at the same time of day. Animal mass was recorded daily
and dexamethasone or prednisolone doses were adjusted
according to changes in body mass.
Twenty-four hours after the last drug administration
(14th day), the animals were anesthetized with sevoflurane.
The left hemidiaphragm with attached phrenic nerve
was rapidly dissected for muscle preparation, and the
right hemidiaphragm was rapidly removed for molecular
assessment.

2.2. Measurement of twitch contractions
The dissected rat phrenic nerve-hemidiaphragm muscle
strips, weighing 90–120 mg and 7–10 mm in length, were
suspended in organ baths in a vertical position, with the
ribs supported on silver electrodes for indirect and direct
stimulations in the organ baths (4 organ baths) containing 10
mL of Krebs solution (NaCl 117 mmol/L; KCl 4.7 mmol/L;
KH2PO 40.9 mmol/L; CaCl2 2.5 mmol/L; NaHCO3 25
mmol/L; glucose 10.1 mmol/L; sodium EDTA 0.03 mmol/L),
bubbled with 5% carbon dioxide and 95% oxygen in air, and
maintained at 37 °C with a pH of approximately 7.40. After
being mounted in the organ baths, each hemidiaphragm
with phrenic nerve was allowed to equilibrate at an optimal
preload tension (1.0–2.0 g) for 60 min. Then the organ
bath solutions were exchanged every 15 min by Krebs
solution during the equilibration period. Isometric twitch
tension was elicited by direct (muscle) or indirect (phrenic
nerve) supramaximal constant-voltage stimulation at 1 Hz
(for 0.05 and for 0.2 ms in the cases of direct and indirect
stimulation, respectively) using a stimulator. Twitch tensions
of phrenic nerve-hemidiaphragm strips were measured
using isometric force transducers (MAY FDT-10A Force
Displacement Transducer (0–50 g), Commat Ltd., Ankara,
Turkey). Normal contraction forces were recorded prior
to the phrenic nerve-hemidiaphragm muscle and then
the phrenic nerve-hemidiaphragm muscle was pretreated
with a sufficient concentration (5 μM) of d-tubocurarine
to totally abolish neuromuscular transmission. After the
twitch tension was stabilized for at least 15 min, maximal
single-twitch tension was determined with an average of
five twitches. Contraction durations were measured for
each phrenic nerve and diaphragm muscle.
2.3. Rocuronium and sugammadex administration
After the elicited twitch tension for 95%–105% of the
initial values (stabilized for 15 min) and baseline twitches
were recorded, 10 µmol/L rocuronium was added to the
Krebs solution. After stabilization of the drug effect, twitch
tensions in the phrenic nerve-hemidiaphragm strips with
rocuronium bromide effect were recorded with at least 10min intervals for 40 min using an MP35 Data Acquisition
System (Biopac System, USA). Finally, while rocuronium
was present in the organ bath, sugammadex (30 µmol/L)
(Bridion, 200 mg/2 mL, Merck Sharp & Dohme Corp Inc.,
USA) was added to the same organ bath and twitch tensions
were determined.
The dry muscle weight was measured and calculated,
and the cross-sectional area was estimated based on the
following formula: muscle weight (g) / [L (cm) × 1.056 (g/
cm3)] (muscle density = 1.056 g/cm3) (20).
2.4. Gene expression analyses from diaphragmatic muscle
tissue
In this study, RNA was isolated from the diaphragmatic
tissues using TRI reagent (Sigma, St. Louis, MO, USA) as
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3. Statistical analysis
At the start of each experimental procedure, twitch
tensions of rat phrenic nerve-hemidiaphragm muscle
strips in all groups were recorded as a reference response
(baseline value). Twitch tensions are expressed in grams
and contraction durations are expressed in milliseconds.
Contractions are expressed as percentages of the initial
reference twitch tension response. Data are presented as
mean ± standard deviation (SD) and percentage and were
analyzed using two-way analysis of variance (ANOVA).
Repeated measures were employed for the comparison of
several group means using the Tukey post hoc Bonferroni
test (SPSS 22, IBM Corp., Armonk, NY, USA). P < 0.05
was considered statistically significant.
4. Results
Twenty-four male rats were used for this experimental
study. No deaths occurred in any groups. There was no
significant difference in the initial body weight of rats (P >
0.05). The animals in group D and group P lost weight but
those in group S gained weight. The daily mean weights of
all animals until the 14th day are shown in Figure 1.
4.1. Isometric twitch contractions
The mean baseline single-twitch tension was lower in both
group D (14.4 ± 1.7 g for muscle, 9.88 ± 0.05 g for nerve)
and group P (12.68 ± 0.05 g for muscle, 11.8 ± 0.9 g for
nerve) than in group S (16.8 ± 0.5 g for muscle, 14.9 ± 0.4
g for nerve) (P < 0.001). When sugammadex was added,
twitch tensions were elevated for all groups. The values
were higher in group S (16.5 ± 0.24 g for muscle, 14.7 ±
0.3 for nerve) than group D (11.7 ± 0.7 g for muscle, 9.6
± 0.03 g for nerve) and group P (11.5 ± 0.78 g for muscle,
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10.54 ± 0.44 g for nerve) (P < 0.001). The percentage of
neuromuscular blockade reversal was lowest in group D.
Data of the single-twitch tension (g) and percentage of
neuromuscular blockade reversal are shown in Table 1.
4.2. The contraction and relaxation properties of the
diaphragm and phrenic nerve
The duration of contractions was significantly shorter
in group D and group P than group S (P < 0.001). The
duration of contractions per group are presented in Table
2. The duration of the relaxation time was longer in group
D than group P and group S (P < 0.001). The percentage of
the reversal of relaxation time is shown in Table 3.
4.3. γ-Subunit gene expression analysis
Gene expression analysis of the nAChRs subunit showed
that the γ-subunit was significantly increased in both the
prednisolone and dexamethasone groups. The increase
of the γ-subunit in group P was higher than in group
D. M-RNA expressions of the nAChRs γ-subunit for all
groups are shown in Figure 2.
5. Discussion
In the present study, the effect of dexamethasone and
prednisolone medication for 14 days on sugammadex
reversal was investigated. We found that sugammadex was
less effective in dexamethasone- and prednisolone-treated
rat diaphragms. Long-term medication with dexamethasone
and prednisolone caused muscle weakness and upregulation
of immature γ-AChR. This upregulation was greater with
prednisolone treatment than dexamethasone. The decrease in
the effectiveness of sugammadex may be due to both muscle
atrophy and the increase in γ-AChR.
320

310

300
Weight (gr)

per the manufacturer’s instructions. On-column DNAse
digestion was performed using a DNAse I kit (QIAGEN,
Valencia, CA, USA). The integrity of the isolated RNA
was verified by running a total of 5 μg of RNA on a 1%
formaldehyde gel. RNA concentration and purity were
measured spectrophotometrically at 260 and 280 nm.
Complementary DNA synthesis was performed using a
High-Capacity cDNA Reverse Transcription Kit (Thermo
Fisher, Grand Island, NY, USA) from the obtained RNA
samples. Expression profiles of cholinergic receptor
nicotinic ɛ (muscle) (Thermo Fisher, Rn00567899_m1)
and cholinergic receptor nicotinic ɣ (muscle) (Thermo
Fisher, Rn00569614_m1) genes were analyzed using
real-time polymerase chain reaction (RT-PCR) with
TaqMan expression assays on an Applied Biosystems 7000
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). Expression levels of all RNA samples
were normalized with actin (Actb) (Thermo Fisher,
Rn00667869_m1), which was used as an endogenous
control.
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Figure 1. Daily weights of the rats. Green line shows saline
group, blue line shows dexamethasone group, red line shows
prednisolone group.
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Table 1. Single-twitch tension elicited by muscle (direct) or phrenic nerve (indirect) stimulation and percentage of reversal. Data are
expressed as mean ± standard deviation. *P < 0.05.
Dexamethasone

Prednisolone

Saline

Twitch tension (g)

Twitch tension (g)

Twitch tension (g)

Muscle

Muscle

Phrenic nerve

Muscle

Phrenic nerve

Phrenic nerve

Baseline

14.4 ± 1.7*

9.88 ± 0.05*

12.68 ± 0.3*

11.8 ± 0.9*

16.8 ± 0.5*

14.9 ± 0.4*

Roc

3.8 ± 0.04*

1.6 ± 0.04*

3.4 ± 0.3*

2.4 ± 0.13*

2.8 ± 0.08*

2.9 ± 0.3*

Roc+Sugam

11.7 ± 0.7*

9.6 ± 0.03*

11.5 ± 0.78*

10.54 ± 0.44*

16.5 ± 0.24*

14.7 ± 0.3*

Percentage of reversal (%)

81.9 ± 7.6*

97.2 ± 0.8*

90.62 ± 5.9*

89.6*

98.3 ± 1.9*

99.9*

Table 2. Duration of contraction (ms) of both diaphragm muscle and phrenic nerve. ANOVA was used. Data are presented as
mean ± standard deviation. Roc: Rocuronium, Sugam: sugammadex. *P < 0.05.

Baseline

Dexamethasone

Prednisolone

Saline

Contraction Duration (ms)

Contraction Duration (ms)

Contraction Duration (ms)

Muscle

Phrenic nerve

Muscle

Phrenic nerve

Muscle

Phrenic nerve

57.8 ± 2.1*

50.1 ± 3.0*

43.7 ± 1.8*

37.7 ± 1.3*

67 ± 1.7*

62.2 ± 0.5*

Roc

50.4 ± 2.5*

40.3 ± 2.6*

36.5 ± 1.3*

36.5 ± 1.2*

40.3 ± 0.5 *

37.2 ± 0.4*

Roc+Sugam

51.03 ± 2*

46.6 ± 1.5*

37.3 ± 0.7*

36.0 ± 1.3*

66.4 ± 0.9*

61.9 ± 0.1*

Percentage of reversal (%)

88.46 ± 5.9*

93.3 ± 4.5*

85.51 ± 4.3* 95.7 ± 4.9*

99.2 ± 2.2*

99.5 ± 0.9*

Table 3. Duration of relaxation (ms) of both diaphragm muscle and phrenic nerve. ANOVA was used. Data are presented as
mean ± standard deviation. Roc: Rocuronium, Sugam: sugammadex.
Dexamethasone

Prednisolone

Saline

Relaxation duration (ms)

Relaxation duration (ms)

Relaxation duration (ms)

Muscle

Phrenic nerve

Muscle

Muscle

Phrenic nerve

Baseline

32.0 ± 1.9

28.7 ± 2.0

27.7 ± 0.9 24.8 ± 1.2

41.1 ± 0.6

40.9 ± 0.2

0.00

Roc

35.9 ± 1.5

32.8 ± 2.2

29.5 ± 1.3 29.0 ± 0.9

48.8 ± 0.6

45.9 ± 0.3

0.00

Roc+Sugam

36.8 ± 2.6

34.5 ± 2.3

27.5 ± 0.9

41 ± 0.1

40.7 ± 0.6

0.00

120.76 ± 13.2

99.54 ± 4.9 97.36 ± 3.9

99.75 ± 1.4 99.5 ± 1.8

0.00

Percentage of reversal (%) 115 ± 11.8

Previous studies showed that fetal-type nAChRs were
resistant to nondepolarizing neuromuscular blockers and
more sensitive to succinylcholine (21,22).
Wang et al. showed that an extended block of synaptic
activity triggered prolongation of end-plate current
deterioration, and when fetal-type AChRs were inhibited
selectively, end-plate current deterioration was reversed at
the neuromuscular junction (23). The authors suggested
that the prolongation of end-plate current deterioration
depended on activation of fetal-type AChRs. Wang et
al. emphasized the selective prolongation of end-plate

Phrenic nerve

24.1 ± 1.0

P

deterioration due to upregulation of fetal-type AChRs.
Thus, neuromuscular transmission will be impaired and
sufficient muscle tone will not be achieved. Their study
supports our hypothesis and results.
The interaction between steroids and neuromuscular
transmission is explained through several mechanisms.
First, glucocorticoids have a facilitator effect on impulse
generation at the neuromuscular junction (24). Second,
glucocorticoids can affect the synthesis and release of
acetylcholine (25,26). Third, they can depress postsynaptic
neuromuscular transmission (27). Rezonja et al. showed
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Figure 2. M-RNA expressions of the nAChRs γ for dexamethasone,
prednisolone, and saline (control) groups.

that dexamethasone treatment impaired functional
innervation by reducing the number of contracting units
in in vitro innervated primary human muscle cells (28).
Chen et al. treated rats with dexamethasone for 14
days and investigated the effect of different neuromuscular
blockers such as rocuronium, vecuronium, and
atracurium on twitch tension and acetylcholine receptor
expression. The researchers concluded that chronic
dexamethasone administration induced hyposensitivity
to nondepolarizing muscle relaxants, which is associated
with increased nAChR expression (15).
Kindler et al. showed that both forms of the
muscle-type acetylcholine receptor were inhibited
by methylprednisolone and hydrocortisone (29). A
combination of vecuronium and methylprednisolone
showed additive effects on muscle-type acetylcholine
receptors. Accordingly, the authors concluded that
neuromuscular blockade was augmented with
pharmacologic denervation when corticosteroids were
combined with vecuronium, resulting in prolonged muscle
weakness.
We used a constant concentration of rocuronium
(10 µmol) and 3-fold sugammadex (30 µmol) for reverse

rocuronium-induced neuromuscular blockade, as used by
Rezonja et al., because previous studies indicated that highdose sugammadex was more effective for neuromuscular
blockade reversal (30,31).
It is widely accepted that sugammadex reverses
neuromuscular blockage by encapsulating steroidal
neuromuscular blocker agents (NMBAs) and removing
the NMBA occupation of the pre- and postjunctional
nicotinic receptor. The main role in the reversal of the
neuromuscular blockade belongs to acetylcholine. If there
is no acetylcholine or motor nerve activity, sugammadex
cannot be effective in neuromuscular blockade reversal
(32). Although sugammadex encapsulates the rocuronium,
neuromuscular transmission deteriorates because immature
nAChRs have a longer open time than the adult form. This
information is the main rationale of our study.
In the present study, despite reversing the
neuromuscular blockade with sugammadex, twitch
tensions and contraction durations did not achieve baseline
values. The percentage of reversal remained at 81.9% and
90.6% for dexamethasone and prednisolone, respectively.
It was also observed that immature nAChRs were active.
Dexamethasone is a fluorinated steroid and has a greater
potency for development of myopathy than prednisolone
(nonfluorinated steroid). (33,34) However, M-RNA
expression of the γ-AChR is 3-fold higher with prednisolone
than dexamethasone, and the percentage of the reversal is
higher with prednisolone. This result can be attributed to
prednisolone causing less myopathy.
Our study has several limitations. First, we did not
measure blood cortisol levels. Second, we used a constant
concentration of both rocuronium and sugammadex and
they were not used in a dose-dependent manner.
In conclusion, long-term use of dexamethasone
and prednisolone causes muscle weakness and induces
resistance to rocuronium-induced neuromuscular blockade,
which can be related to upregulation of immature nAChR
(γ-AChR). Furthermore, these medications attenuate the
reversal effect of sugammadex on rocuronium-induced
neuromuscular blockade. This was an animal study;
therefore, further clinical studies in humans are needed to
clarify the effect of long-term glucocorticoid medication on
sugammadex reversal.
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